A PHASE IB STUDY OF ISATUXIMAB PLUS POMALIDOMIDE (POM) AND DEXAMETHASONE (DEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

被引：0
|
作者：
Mikhael, J. [1 ]
Richardson, P. [2 ]
Usmani, S. [3 ]
Raje, N. [4 ]
Bensinger, W. [5 ]
Kanagavel, D. [6 ]
Gao, L. [7 ]
Ziti-ljajic, S. [6 ]
Anderson, K. [2 ]
机构：
[1] Mayo Clin, Phoenix, AZ USA
[2] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[3] Levine Canc Inst, Charlotte, NC USA
[4] Massachusettes Gen Hosp, Boston, MA USA
[5] Swedish Canc Inst, Myeloma & Transplant Program, Seattle, WA USA
[6] Sanofi, Vitry Sur Seine, France
[7] Sanofi Oncol, Cambridge, MA USA
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S457
引用
收藏
页码：168 / 168
页数：1
相关论文
共 50 条
  • [1] Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)
    Richardson, Paul G.
    Mikhael, Joseph
    Usmani, Saad Z.
    Raje, Noopur
    Bensinger, William
    Kanagavel, Dheepak
    Gao, Lei
    Ziti-Ljajic, Samira
    Anderson, Kenneth C.
    [J]. BLOOD, 2017, 130
  • [2] Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM).
    Mikhael, Joseph
    Richardson, Paul G.
    Usmani, Saad Zafar
    Raje, Noopur S.
    Bensinger, William
    Dubin, Franck
    Liu, Qianying
    Vitse, Olivier
    Anderson, Kenneth Carl
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Preliminary Results From a Phase Ib Study of Isatuximab in Combination with Pomalidomide (Pom) and Dexamethasone (Dex) in Relapsed and Refractory Multiple Myeloma (RRMM)
    Richardson, Paul
    Mikhael, Joseph
    Usmani, Saad
    Raje, Napoor
    Bensinger, William
    Campana, Frank
    Gao, Lei
    Dubin, Franck
    Wack, Claudine
    Anderson, Kenneth C.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E16 - E17
  • [4] A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183.
    Mateos, Maria-Victoria
    Blacklock, Hilary
    Schjesvold, Fredrik
    Rocafiguera, Albert Oriol
    Simpson, David
    George, Anupkumar
    Goldschmidt, Hartmut
    Larocca, Alessandra
    Sherbenou, Daniel Wayne
    Avivi, Irit
    Iida, Shinsuke
    Matsumoto, Morio
    Usmani, Saad Zafar
    Jagannath, Sundar
    Rodriguez-Otero, Paula
    Kher, Uma
    Farooqui, Mohammed Z. H.
    Liao, Jason
    Marinello, Patricia
    Lonial, Sagar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] A phase III, randomized, open-label study of isatuximab (SAR650984) plus pomalidomide (Pom) and dexamethasone (Dex) versus Pom and Dex in relapsed/refractory multiple myeloma.
    Richardson, Paul G.
    Attal, Michel
    Miguel, Jesus San
    Campana, Frank
    Le-Guennec, Solenn
    Hui, Ai-Min
    Risse, Marie-Laure
    Anderson, Kenneth Carl
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] A phase 1/2 study of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM)
    Berenson, James R.
    Klein, Leonard M.
    Rosen, Peter J.
    Woliver, Thomas B. S.
    Eshaghlan, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design
    Richardson, Paul G.
    Attal, Michel
    Campana, Frank
    Le-Guennec, Solenn
    Hui, Ai-Min
    Risse, Marie-Laure
    Corzo, Kathryn
    Anderson, Kenneth C.
    [J]. FUTURE ONCOLOGY, 2018, 14 (11) : 1035 - 1047
  • [8] A PHASE III RANDOMIZED, OPEN-LABEL STUDY OF ISATUXIMAB (SAR650984) PLUS POMALIDOMIDE AND DEXAMETHASONE VERSUS POM AND DEX IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Richardson, P.
    Attal, M.
    San Miguel, J.
    Campana, F.
    Le-Guennec, S.
    Hui, A. -M.
    Risse, M. -L.
    Anderson, K.
    [J]. HAEMATOLOGICA, 2017, 102 : 779 - 779
  • [9] Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Richardson, Paul G.
    Mikhael, Joseph
    Usmani, Saad Z.
    Raje, Noopur
    Bensinger, William
    Campana, Frank
    Gao, Lei
    Dubin, Franck
    Wack, Claudine
    Anderson, Kenneth C.
    [J]. BLOOD, 2016, 128 (22)
  • [10] A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
    Mikhael, Joseph
    Richardson, Paul
    Usmani, Saad Z.
    Raje, Noopur
    Bensinger, William
    Karanes, Chatchada
    Campana, Frank
    Kanagavel, Dheepak
    Dubin, Franck
    Liu, Qianying
    Semiond, Dorothee
    Anderson, Kenneth
    [J]. BLOOD, 2019, 134 (02) : 123 - 133
12345